Compare CHRS & NAKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHRS | NAKA |
|---|---|---|
| Founded | 2010 | 2019 |
| Country | United States | United States |
| Employees | N/A | 61 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.8M | 196.8M |
| IPO Year | 2014 | N/A |
| Metric | CHRS | NAKA |
|---|---|---|
| Price | $1.27 | $4.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $5.51 | $0.75 |
| AVG Volume (30 Days) | ★ 690.4K | 188.5K |
| Earning Date | 05-07-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 472.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $73.08 | $1,514.38 |
| Revenue Next Year | $30.94 | $48.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.83 | $0.15 |
| 52 Week High | $2.62 | $16.47 |
| Indicator | CHRS | NAKA |
|---|---|---|
| Relative Strength Index (RSI) | 35.60 | 57.90 |
| Support Level | $1.15 | $4.12 |
| Resistance Level | $1.44 | $5.11 |
| Average True Range (ATR) | 0.08 | 0.44 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 34.01 | 76.15 |
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
Nakamoto Inc is a Bitcoin company building a world-wide portfolio of Bitcoin-native companies to provide commercial and financial infrastructure for the next generation of capital markets.